33 results about "Poly l arginine" patented technology

Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and / or transport therapeutic drugs across the blood brain barrier.

The application discloses a kind of R8 and Tf co-modified mebendazole liposome targeted preparation and its preparation method, application, belong to the field of biological medicine. In view of the poor solubility of mebendazole in water, difficult to penetrate blood-brain barrier, the problem of insufficient tumor targeting in brain glioma treatment, the application adopts film hydration-step modification process, and octaarginine (R8) and targeting ligand transferrin (Tf) are simultaneously modified on the surface of mebendazole-loaded liposome, and the preparation prepared by the application has an encapsulation efficiency of not less than 95%. The preparation can break through blood-brain barrier and precisely enrich in brain glioma lesions, and the in-vivo tumor inhibition rate is more than 90%, with low toxicity and side effects. The preparation can be used for preparing brain glioma therapeutic drugs, and provides a new drug for targeted treatment of brain glioma.

The invention discloses a macrophage immune activation method based on aggregate mediated magnesium ion delivery. The method comprises the following steps: in a buffer environment containing magnesium ions, preparing a biomolecular aggregate formed by compounding polyarginine and polyadenylic acid through liquid-liquid phase separation, and enriching the magnesium ions by the aggregate through multivalent chelation; diluting the aggregate loaded with high-concentration magnesium ions in a cell culture medium to obtain a biomolecular aggregate suspension; and sequentially adding the target cell suspension and the biomolecular aggregate suspension into a cell culture dish, fully mixing, and then transferring the cell culture dish into a carbon dioxide cell incubator for standing culture. According to the method, the biomolecular aggregate loaded with the high-concentration magnesium ions is co-cultured with the cells, and the high-concentration magnesium ions are delivered into the cells in a short time, so that the immune level of the cells is improved, and the activity and safety of the cells are ensured.

The invention relates to a wound dressing (2) for wound treatment in a moist or moist / wet environment, having a fibrous nonwoven-based absorbing / rinsing body (4) in which superabsorbent material is received in a distributed manner, wherein a saline aqueous solution, in particular Ringer's solution, is applied to the absorbing / rinsing body (4) by the manufacturer, and having a cover (6) forming the outer visible sides of the wound dressing, wherein the cover (6) comprises, on the wound-facing side of the wound dressing, a textile surface material (9), in particular composed of a weft-knitted fabric, warp-knitted fabric or woven fabric, wherein the cover (6) has, on the wound-facing side of the wound dressing, an antimicrobial coating (22) which has been applied to part or all of the outer side and which comprises a hyaluronic acid and a polypeptide chosen from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides.

The application discloses an activatable cell-penetrating peptide, a preparation method, a drug delivery method and an application thereof. The activatable cell-penetrating peptide comprises polypeptide segment 1 and polypeptide segment 2; the polypeptide segment 1 comprises a peptide chain 1, the N terminal of the peptide chain 1 is acetylated and connected with a cyclic peptide RGD, and a group with a cyano group is further connected to the peptide chain 1; the polypeptide segment 2 comprises a peptide chain 2, the N terminal of the peptide chain 2 is also connected with a cyclic peptide RGD, and the peptide chain 2 contains cysteine. The application designs a novel strategy of in-situ activatable cell-penetrating peptide based on an activation nitrile-amino thiol coupling reaction, and the cell-penetrating peptide is composed of two independent low cell-penetrating activity polyarginine polypeptides; after reaching a target site, the two are coupled in-situ through the above-mentioned click chemistry reaction to generate an octa-arginine sequence with high cell-penetrating ability. The design of the 'on-demand activation' not only restores the cell-penetrating function, but also significantly reduces the cytotoxicity caused by non-specific penetration.

The invention relates to a silicone-containing, antimicrobial wound contact layer having, on the wound side, a partial or complete antimicrobial coating comprising i) a hyaluronic acid and ii) a polypeptide selected from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides. The invention also relates to absorbent wound dressings containing said wound contact layer, and to methods for producing the wound contact layer.

The application belongs to the field of fertilizers, and particularly relates to a high-nitrogen-fertilizer utilization rate foliar fertilizer and a preparation method thereof. Glycidyl methacrylate is used to prepare a polymer, and then polyarginine is used to modify the polymer to obtain a composite matrix. Part of the composite matrix is combined with 3,4,9,10-perylenetetracarboxylic dianhydride to obtain a photosensitive matrix. The photosensitive matrix is used as a ligand, metal ions are combined with the ligand to form a complex, and the complex is compounded with the composite matrix and soluble compounds of nutrient elements to obtain the foliar fertilizer. The high-nitrogen-fertilizer utilization rate foliar fertilizer can promote photosynthesis of plants, promote root growth, and improve nitrogen absorption and utilization of plants.

The invention discloses a degradable magnesium alloy intravascular stent based on bionic hydrogel and nitric oxide double-path release and a preparation method and application thereof. The method comprises the steps that a magnesium alloy base material is subjected to alkali heat treatment; immersing the treated magnesium alloy into a silane coupling agent for reaction; the photopolymerization reaction liquid is treated to the surface of the silanization modified magnesium alloy, and polymerization is conducted through ultraviolet irradiation; immersing the magnesium alloy with the hydrogel coating into a polyarginine solution, and grafting polyarginine onto the surface of the hydrogel; a sample is activated through EDC / NHS and then immersed in a selenocystamine solution for a reaction, and the bionic composite coating, with the exogenous / endogenous dual-path nitric oxide release function, of the degradable magnesium alloy intravascular stent is obtained. The invention successfully constructs the bionic coating integrating cell membrane-imitating anti-fouling and exogenous / endogenous dual-path NO release functions, and the coating effectively solves the key problems of corrosion control, thrombus formation resistance, functional re-endothelialization coordinated regulation and the like faced by the degradable magnesium alloy intravascular stent.

The invention belongs to the technical field of biological medicine, and particularly discloses fluorouracil sustained-release nano-microspheres as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, dissolving fluorouracil in a polyarginine aqueous solution, uniformly stirring, and adjusting the pH value to 7.2-7.4 to obtain a fluorouracil solution; s2, dissolving amphiphilic alginate in water, sequentially adding carboxymethyl chitosan and quaternized gelatin, and uniformly stirring to obtain a composite carrier solution; and S3, mixing the fluorouracil solution obtained in the step S1 with the composite carrier solution obtained in the step S2, performing ultrasonic treatment, performing self-assembly, performing centrifugation, and collecting precipitates to obtain the fluorouracil nano-microspheres. The invention discloses a fluorouracil sustained-release nano-microsphere as well as a preparation method and application thereof. The fluorouracil sustained-release nano-microsphere can be used for remarkably improving the encapsulation efficiency and the drug loading capacity of fluorouracil, realizing long-acting sustained release of drugs, enhancing the tumor targeting property and the cell uptake efficiency and improving the treatment effect.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

A recombinant TEV protease, a preparation method therefor, and use thereof, relating to the technical field of biology. Specifically provided are four recombinant TEV proteases derived from a cysteine protease of tobacco etch virus. In each of the four recombinant TEV proteases, the N-terminus is fused with an 8His-CL7-GGS tag, and the C-terminus is fused with a polyarginine tag. Compared to a wild-type TEV protease, the provided four recombinant TEV proteases not only can overcome defects such as self-cleavage, poor solubility, and low activity during expression and purification of the wild-type TEV protease, but also have improved protein yield 5-6 times higher than that of the wild-type TEV enzyme, and enzyme activity 10-20 times higher than that of the wild-type TEV protease. In addition, the engineered TEV protease mutants also possess higher thermal stability with a Tm value 10-30 °C higher than that of the wild-type TEV protease, exhibit better protein stability, have broader application conditions, and are more suitable for large-scale production and industrial use.

The invention relates to a wound covering comprising at least one plastic mesh and one absorbent non-woven material, wherein at least the mesh has an antimicrobial coating. The coating comprises a hyaluronic acid and a polypeptide selected from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides. The invention also relates to methods for applying the coating, and to wound coverings comprising the antimicrobial non-woven fabric. The coating is distinguished by its good compatibility and cell compatibility as well as its strong antiseptic action.

The present invention relates to a method for preparing linear polylysine or polyarginine by chemoenzymatic bulk polymerization of lysine esters or arginine esters, respectively. The invention also relates to a method for controlling the regioselectivity of polylysine or polyarginine in the chemoenzymatic bulk polymerization of lysine esters or arginine esters.

Particles are provided that include (a) a liposome having a negatively charged outer surface; (b) a first layer comprising poly-L-arginine (PLR), wherein the PLR is non-covalently associated with the negatively charged outer surface of the liposome; (c) a second layer, comprising hyaluronate (HA), wherein the HA is non-covalently associated with the first layer; and (d) a blood brain barrier-targeting peptide layer electrostatically coupled to the second layer; as are particles that are loaded with a therapeutic and their use for treating a brain cancer.

Provided are polyarginine polypeptide ASIC inhibitors, pharmaceutical compositions comprising the same as well as methods and uses therefor In particular, the present disclosure relates to the methods and uses of such polypeptides or pharmaceutical compositions in the treatment of ASIC-related diseases. Such polypeptides or pharmaceutical compositions are useful to treat neurological disorders, neurodegenerative diseases, psychological disorders, sexual disorders, cardiovascular diseases, respiratory diseases, inflammatory diseases, renal diseases, gastrointestinal diseases, metabolic disorders, cancer, and addiction, e.g. smoking addiction.

The present disclosure provides polypeptide conjugates comprising a cell-penetrating peptide (CPP), directly or indirectly attached to a group comprising at least one peptide or polyamine, such as a polyarginine peptide.

The application discloses a kind of ternary co-modified engineering velvet MSCs exosomes and preparation method and application thereof, belong to the biomedicine technical field, it includes velvet MSCs exosomes, polyarginine polypeptide-deoxyribonuclease I complex located on the surface of velvet MSCs exosome, and RGD polypeptide with Arg-Gly-Asp sequence modified on the surface of velvet MSCs exosome.The purpose is to solve the problem that the "integration" treatment mode of multiple pathological links cannot be realized when existing RA is treated, for the first time, three active components polyarginine polypeptide (P-Arg), deoxyribonuclease I (Dnase I) and RGD polypeptide are modified on the surface of velvet MSCs exosome, to form surface engineered modified exosome complex, multiple functions of immune regulation, cfDNA removal, targeted delivery and tissue protection can be realized in RA lesion, and a new, systematic treatment method is provided for rheumatoid arthritis.

The invention discloses a polypeptide type preparation in the field of polypeptide type preparations. The polypeptide type preparation is prepared from the following components in parts by weight: PLGA (poly (lactic-co-glycolic acid)), PLGA-PEG-COOH, PEI (polyetherimide), a high-permeability factor, rhNGF (recombinant human neurotrophic growth factor), mannitol and cane sugar. Through a mode of combining octamer arginine and cyclized peptide, the penetrability of the rhNGF and the specificity to a targeting group are improved, non-target tissue distribution is reduced, the drug effect is improved, the toxic and side effects are reduced, the rhNGF is loaded by adopting a reaction of combining hydrophobic acting force and electrostatic acting force, the slow release effect on the rhNGF is realized, and the preparation method is simple and convenient. The disulfide bond cyclization in the cyclized peptide improves the enzymolysis resistance and oxidation resistance of the targeting molecule, solves the problems of penetration, targeting and stability of the rhNGF from the molecular level, and provides an efficient, safe and long-acting preparation solution for nerve injury repair.

The invention provides a multifunctional antigen and adjuvant co-delivered virus mimic vaccine and a preparation method thereof. The vaccine is composed of a spherical nanogel core containing CpG nucleic acid and a bionic virus spike structure outer layer, the core structure is formed by self-assembly of a Y-type nucleic acid scaffold containing a TLR9 agonist and a linear connector through base complementation, the outer layer is RBD antigen and polyarginine fusion protein, and non-covalent wrapping is achieved through a salt bridge zipper mechanism. The vaccine can efficiently enter lymph nodes through intramuscular injection, activate innate immunity and adaptive immune response and induce strong antigen-specific immune response, has the advantages of improving immunogenicity, enhancing immune effect, being strong in stability and the like, is suitable for solving the problem of poor immune effect of subunit vaccines, and has a wide application prospect.

The present technology is directed to nanoparticle compositions and methods useful in treating RHAMM-positive cancers. Such nanoparticle compositions include a plurality of nanoparticles where each nanoparticle includes (i) a particle core with an outer surface; a first layer coating the outer surface of the particle core, the first layer including one or both of poly-L-lysine and poly-L-arginine and optionally including a fluorescent dye; a second layer coating the first layer, the second layer including one or more siRNA that inhibit expression of Bcl-2, inhibit expression of Bcl-xL (BCL2L1), inhibit expression of MCL1, inhibit expression of Bcl-w (BCL2L2), inhibit expression of Bcl-b (BCL2L10), and / or inhibit expression of BFL1 (BCL2A1); a third layer coating the second layer, the third layer including an apoptotic peptide and optionally including a fluorescent dye; and a fourth layer coating the third layer, the fourth layer including hyaluronic acid or a pharmaceutically acceptable salt thereof (HA); and where the plurality of nanoparticles has an intensity-weighted average diameter as determined by dynamic light scattering from about 100 nm to about 300 nm; or (ii) a particle core with an outer surface; a first layer coating the outer surface of the particle core, the first layer including an apoptotic peptide and optionally including a fluorescent dye; a second layer coating the first layer, the second layer including one or more siRNA that inhibit expression of Bcl-2, inhibit expression of Bcl-xL (BCL2L1), inhibit expression of MCL1, inhibit expression of Bcl-w (BCL2L2), inhibit expression of Bcl-b (BCL2L10), and / or inhibit expression of BFL1 (BCL2A1); a third layer coating the second layer, the third layer including one or both of poly-L-lysine and poly-L-arginine and optionally including a fluorescent dye; and a fourth layer coating the third layer, the fourth layer including hyaluronic acid or a pharmaceutically acceptable salt thereof (HA); and where the plurality of nanoparticles has an intensity-weighted average diameter as determined by dynamic light scattering from about 100 nm to about 300 nm.

The invention belongs to the field of medical materials, and particularly relates to a tissue adhesive as well as a preparation method and a curing method thereof. The tissue adhesive provided by the invention is prepared from long-chain alkyl modified polyarginine, a polyphenol-metal coordination compound, riboflavin and water, the carbon atom number of the long-chain alkyl group is 10-20; the polyphenol-metal coordination compound is prepared by reacting a natural polyphenol compound with metal ions. The components of the tissue adhesive are optimally designed, so that the tissue adhesive can be quickly cured under the blue light irradiation condition, and meanwhile, the injectability, the strong adhesive property, the long-term stable adhesion, the biocompatibility, the anti-inflammatory property and the healing promoting property are considered.

The application discloses a microneedle co-loading asiaticoside and near-infrared photothermal agents, and a preparation method and application thereof. The microneedle adopts a layered structure, and hyaluronic acid and polyvinylpyrrolidone are used as a skeleton matrix. Asiaticoside, near-infrared photothermal agent IR1048 and octa-arginine are loaded on the needle tip, and asiaticoside is loaded on the base. The mechanical strength of a single needle is about 0.46 N, the needle can smoothly penetrate into the dermis layer and is basically dissolved within 10 min, and in-situ precise release of active ingredients is realized. In combination with 1064 nm laser irradiation, the application degrades amyloid in the dermis layer through the photothermal effect of IR1048, and cooperates with asiaticoside to inhibit abnormal cell proliferation and promote collagen regeneration, so that the lesion is effectively removed and the skin microenvironment is reshaped. The microneedle has no obvious skin irritation, has good blood compatibility, and has no systemic toxicity. The application provides a safe and efficient transdermal delivery new strategy with clinical conversion potential for skin amyloidosis.

The present invention relates to a wound contact layer comprising a net-like substrate which has a partial or full antimicrobial coating. The coating comprises hyaluronic acid and a polypeptide selected from polyarginine and / or polylysine. Methods for applying the coating to the wound contact layer are additionally described. The coating is distinguished by its good compatibility and cell compatibility as well as its strong antiseptic action.

The invention relates to a non-woven fabric for wound treatment, said fabric having a partial or full antimicrobial coating. The coating comprises a hyaluronic acid and a polypeptide selected from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides. The invention also relates to methods for applying the coating to the non-woven fabric, and additionally relates to wound dressings comprising the antimicrobial non-woven fabric. The coating is distinguished by its good compatibility and cell compatibility as well as its strong antiseptic action.

The invention relates to the technical field of biological medicine, and particularly discloses a cell-penetrating peptide composition and application thereof in preparation of cosmetics. The cell-penetrating peptide composition is prepared from 9-polyarginine and 8-polylysine, wherein the 9-polyarginine and the 8-polylysine are used as raw materials; wherein the weight ratio of 9-polyarginine to 8-polylysine is (1-5): (1-5). The cell-penetrating peptide composition disclosed by the invention is prepared from 9-polyarginine and 8-polylysine; compared with single use of 9-polyarginine and 8-polylysine, the composite cell-penetrating peptide used in the invention has better cell-penetrating ability and synergistic cell-penetrating ability; the composition can be applied to cosmetics, so that active substances in the cosmetics can be fully absorbed and utilized; the cell-penetrating peptide can efficiently promote a plurality of active substances to enter cells in vivo and in vitro and significantly improve the transmembrane transport efficiency of the active substances, so that the concentration of the active substances in the cells is improved, and the cell-penetrating peptide has no toxic effect on the cells, does not generate immune response, and achieves the transmembrane transport effect which cannot be achieved by a single cell-penetrating peptide.

The invention belongs to the technical field of drug-loaded gel materials, and particularly relates to a preparation method of borneol-skin penetrating peptide composite in-situ gel and a textile-based drug-loaded system. The borneol and the skin penetrating peptide are bridged together through an azone structure, and the prepared borneol-skin penetrating peptide compound contains a lipophilic aliphatic chain, a keto group and a hydrophilic amino group, has a branched structure and a relatively large molecular weight, and can effectively improve the emulsification dispersion effect of a system, so that the particle size of the nano-emulsion is reduced, and the preparation method is simple and convenient. The distribution uniformity of the particle size of the nano-emulsion is improved. One end of the borneol-skin penetrating peptide compound molecule is of a borneol structure, the other end of the borneol-skin penetrating peptide compound molecule is of a polyarginine structure, an azone structure is contained on a middle chain segment, and the borneol-skin penetrating peptide compound molecule, the polyarginine structure and the azone structure jointly play a role and cooperate to improve the transdermal absorption effect.

The application discloses a nano prodrug for releasing nitric oxide gas by ultrasonic piezoelectric catalysis effect and a preparation method and application thereof. 2000 The nano prodrug is formed by covalently coupling a nitric oxide precursor poly-L-arginine and a phospholipid DSPE-PEG -NH2 through an amidation reaction to form an amphiphilic prodrug molecule, and then encapsulating a nano piezoelectric material barium titanate to form the nano prodrug, which is accumulated in tumor tissues through enhanced permeation and retention effect, and generates a piezoelectric effect by using ultrasonic waves to stimulate the barium titanate, so that water molecules generate singlet oxygen, hydrogen peroxide and oxygen, and then the polyarginine is oxidized to release nitric oxide; the process is independent of oxygen and can produce oxygen, and is suitable for treatment of hypoxic tumors. The application further discloses application of the nano particles in breast cancer treatment, and the nano particles have good biocompatibility and remarkable effects of inhibiting tumor growth and metastasis, and have an advantage of being not limited by a tumor microenvironment compared with existing NO controlled release technology.

The present application relates to a kind of polyarginine-DNA nanotube material and its preparation method and application, belong to the field of biological medicine.The existing DNA nanomaterial is dependent on magnesium ion, which leads to unstable structure, low cell uptake rate and easy degradation by nuclease.The present application is formed by four DNA single strands (Y1-Y4) self-assembly according to the molar ratio 1:3:3:3 nanotube material induced by polyarginine.The material can load p65 siRNA to form a complex preparation, which is used for preparing a drug for inhibiting lung inflammation.The polyarginine-DNA nanotube material of the present application significantly improves the stability and cell uptake efficiency of the material;The higher the degree of polymerization of arginine, the stronger the anti-inflammatory activity;The complex preparation inhibits the expression of pro-inflammatory factors through the double mechanism of blocking inflammatory pathways by polyarginine and silencing p65 signal by p65 siRNA, providing an efficient delivery vector for the treatment of acute lung injury.

The invention discloses bilirubin and blood ammonia affinity modified filler for blood purification and a preparation method thereof, and belongs to the technical field of blood purification. The preparation method comprises the following steps: firstly, carrying out surface activation on an inert resin base material by adopting a plasma coating physical method, and then grafting and crosslinking a layer of guanidyl chitosan, so that the filler is endowed with excellent biocompatibility and hydrophilicity by the layer, and the rich guanidyl structure of the guanidyl chitosan can play a strong specific affinity adsorption role on blood ammonia in blood; a functional outer layer for targeted adsorption of bilirubin is constructed, polyarginine is further grafted on the functional outer layer, a high-density guanidyl functional area is formed on the layer, bilirubin combined with albumin can be efficiently and selectively captured through multiple mechanisms such as ionic bonds and pi-cation interaction, and the bilirubin targeted adsorption function is obtained. Two key pathogenic factors in hepatic failure can be efficiently removed at the same time, and the adaptation disease range of the hemoperfusion device is greatly widened.

The invention provides a polyarginine protamine antibacterial peptide as well as a preparation method and application thereof, and belongs to the technical field of active peptide preparation. The polypeptide provided by the invention is separated and identified from sturgeon protamine, and the sequence rule and antibacterial activity of the separated target derived peptide are determined through amino acid sequence identification and in-vitro bacterial experiments. The polyarginine type cationic antibacterial peptide provided by the invention is prepared through acid extraction, alcohol precipitation, molecular sieve chromatography and cation exchange chromatography technologies, and in-vitro bacteriostasis experiments prove that the polyarginine type cationic antibacterial peptide can play a remarkable role in inhibiting and killing various bacteria including salmonella pullorum. The raw materials adopted by the invention are natural, high in safety and biocompatibility, and suitable for development of antibiotic substitute products and related drugs thereof.